Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study

INTRODUCTION: While coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV G...

Descripción completa

Detalles Bibliográficos
Autores principales: Liou, Bo-Huang, Sun, Hsin-Yun, Yang, Chia-Jui, Syue, Ling-Shan, Lee, Yu-Lin, Tang, Hung-Jen, Tsai, Hung-Chin, Lin, Chi-Ying, Chen, Tun-Chieh, Lee, Chun-Yuan, Huang, Sung-Hsi, Liu, Chia-Wei, Lu, Po-Liang, Lin, Shih-Ping, Wang, Ning-Chi, Cheng, Aristine, Ko, Wen-Chien, Cheng, Shu-Hsing, Hung, Chien-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116398/
https://www.ncbi.nlm.nih.gov/pubmed/33733316
http://dx.doi.org/10.1007/s40121-021-00424-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116398/
https://www.ncbi.nlm.nih.gov/pubmed/33733316
http://dx.doi.org/10.1007/s40121-021-00424-8

Ejemplares similares